News
-
-
PRESS RELEASE
Selective PPARα Modulator "K-808" (Pemafibrate) Granted "Breakthrough Therapy" Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis
Kowa Company Ltd. receives Breakthrough Therapy designation from FDA for "K-808" (pemafibrate) as a treatment for Primary Biliary Cholangitis, aiming to provide new treatment options for patients -
-
PRESS RELEASE
K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Kowa Company Ltd. to present non-clinical data for novel antibody drug-loaded unimicelle conjugate K-679 at AACR Annual Meeting 2026 showcasing tumor-selective pharmacokinetics
